Kalon is a biopharmaceutical contract manufacturing organization with advanced technologies and facilities.
It is a key subcontractor to one of the three Centers for Innovation in Advanced Development and Manufacturing awarded by the US Department of Health and Human Services, Biomedical Advanced Research and Development Authority.
This is intended to develop and manufacture medical countermeasures to protect public health in emergencies, including incidents of bioterrorism or an outbreak of pandemic influenza.
The acquisition will provide Fujifilm Diosynth with expanded capacity for its growing vaccine capabilities.
Fujifilm Diosynth Biotechnologies CEO Steve Bagshaw said: "This acquisition further reinforces Fujifilm’s global leadership and commitment to the biopharmaceutical industry.
"Our scientific and manufacturing leadership will be strengthened by adding Kalon’s viral and cell culture vaccine expertise and capabilities to our existing competencies in microbial, mammalian and insect cell process development, analytics, and commercial production."
Image: Fujifilm Diosynth Biotechnologies produces recombinant proteins, vaccines, monoclonal antibodies expressed in a wide array of microbial, mammalian, and insect cell line systems. Photo: courtesy of BusinessWire.